Document:

Exchange and Registration Rights Agreement

 Exhibit 10.2 
 EXECUTION VERSION 
 TENET HEALTHCARE CORPORATION 
 8 7/8%
Senior Secured Notes due 2019 
 unconditionally guaranteed as to the 
 payment of principal, premium, 
 if
any, and interest by the 
 Guarantors named on Schedule I hereto 
  
  
 Exchange and Registration Rights Agreement 
 June 15, 2009 
 Banc of America Securities LLC 
 One Bryant Park 
 New York, NY 10036 
 Goldman,
Sachs & Co. 
 85 Broad Street 
 New York, NY 10004

 Citigroup Global Markets Inc. 
 388 Greenwich Street

 New York, NY 10013 
 As Representatives of the
Initial Purchasers 
 Ladies and Gentlemen: 
 Tenet Healthcare Corporation, a Nevada corporation (the “Company”), is issuing, on the date hereof, $925,000,000 in aggregate principal amount of its 8 7/8% Senior Secured Notes due 2019 (the “Notes”), which are unconditionally guaranteed by the Guarantors (as defined herein), upon the terms and conditions
set forth in that certain Offering Memorandum, dated June 1, 2009, as amended and supplemented, and that certain Purchase Agreement (the “Purchase Agreement”), dated as of June 1, 2009, among the Company, Banc of America
Securities LLC, Goldman, Sachs & Co., Citigroup Global Markets Inc., Scotia Capital (USA) Inc., Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Wachovia Capital Markets, LLC. As an inducement to purchase the Notes, and in
satisfaction of a condition to the obligations of the Company under the Purchase Agreement, the Company and the Guarantors agree with the Initial Purchasers (as defined herein), for the benefit of the holders (as defined herein) from time to time of
the Registrable Securities (as defined herein), as follows: 
 1. Certain Definitions. For purposes of this Exchange and
Registration Rights Agreement (this “Agreement”), the following terms shall have the following respective meanings: 
 “Base Interest” shall mean the interest that would otherwise accrue on the Securities under the terms thereof and the Indenture, without giving effect to the provisions of this Agreement. 
 The term “broker-dealer” shall mean any broker or dealer registered with the Commission under the Exchange Act. 

 “Business Day” shall mean each Monday, Tuesday, Wednesday, Thursday and Friday that is
not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to be closed. 
 “Closing Date” shall mean the date on which the Securities are initially issued. 
 “Commission”
shall mean the United States Securities and Exchange Commission, or any other federal agency at the time administering the Exchange Act or the Securities Act, whichever is the relevant statute for the particular purpose. 
 “Company” shall have the meaning assigned thereto in the preamble. 
 “Consummation Date” shall have the meaning assigned thereto in Section 2(a) hereof. 
 “Effective Time” shall mean the time and date as of which the Commission declares the Exchange Registration Statement effective or as of
which the Exchange Registration Statement otherwise becomes effective. 
 “Exchange Act” shall mean the Securities Exchange
Act of 1934, or any successor thereto, as the same shall be amended from time to time. 
 “Exchange Offer” shall have the
meaning assigned thereto in Section 2(a) hereof. 
 “Exchange Registration” shall have the meaning assigned thereto in
Section 3(c) hereof. 
 “Exchange Registration Statement” shall have the meaning assigned thereto in Section 2(a)
hereof. 
 “Exchange Securities” shall have the meaning assigned thereto in Section 2(a) hereof. 
 “FINRA” shall mean the Financial Industry Regulatory Authority, Inc. 
 “Free Trade Date” shall mean the 380th day following the Closing Date. 
 “Freely Tradable” shall mean, with respect to the Securities at any time of determination, that (a) all outstanding Securities are eligible to be sold by a person who has not been an
“affiliate” (as defined in Rule 405 under the Securities Act) of the Company or any Guarantor during the preceding 90 days without any volume or manner of sale restrictions under the Securities Act, (b) the Company has provided a
certificate to the Trustee instructing the Trustee that the restrictive legend on the Securities no longer applies and (c) the Securities have been assigned an unrestricted CUSIP number. 
 “Guarantors” shall have the meaning assigned thereto in the Indenture. 
 The term “holder” shall mean each of the persons who acquire Registrable Securities from time to time (including any successors or
assigns), in each case for so long as such person owns any Registrable Securities. 
 “Indenture” shall mean the Indenture,
dated November 6, 2001, between the Company and The Bank of New York Mellon Trust Company, N.A., as successor to The Bank of New York, as supplemented by the Eleventh Supplemental Indenture, dated as of June 15, 2009, among the Company,
the Guarantors and the Trustee, as the same shall be supplemented or amended from time to time. 
  

 2 

 “Initial Purchasers” shall mean Banc of America Securities LLC, Goldman,
Sachs & Co., Citigroup Global Markets Inc., Scotia Capital (USA) Inc., Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Wachovia Capital Markets, LLC. 
 “Notes” shall have the meaning assigned thereto in the preamble. 
 The term “person” shall mean a corporation, association, partnership, organization, business, individual, government or political
subdivision thereof or governmental agency. 
 “Purchase Agreement” shall have the meaning assigned thereto in the preamble.

 “Registrable Securities” shall mean the Securities; provided, however, that a Security shall cease to be a
Registrable Security when (a) in the circumstances contemplated by Section 2(a) hereof, the Security has been exchanged for an Exchange Security in an Exchange Offer as contemplated in Section 2(a) hereof (provided that any
Exchange Security that, pursuant to the second to last and third to last sentences of Section 2(a), is included in a prospectus for use in connection with resales by broker-dealers shall be deemed to be a Registrable Security with respect to
Sections 5, 6 and 9 until resale of such Registrable Security has been effected within the 180-day period referred to in Section 2(a)); (b) the Securities become Freely Tradable or (c) such Security shall cease to be outstanding.

 “Registration Default” shall have the meaning assigned thereto in Section 2(b) hereof. 
 “Registration Default Period” shall have the meaning assigned thereto in Section 2(b) hereof. 
 “Registration Expenses” shall have the meaning assigned thereto in Section 4 hereof. 
 “Resale Period” shall have the meaning assigned thereto in Section 2(a) hereof. 
 “Restricted Holder” shall mean (i) a holder that is an affiliate of the Company within the meaning of Rule 405, (ii) a holder
who acquires Exchange Securities outside the ordinary course of such holder’s business, (iii) a holder who has arrangements or understandings with any person to participate in the Exchange Offer for the purpose of distributing Exchange
Securities and (iv) a holder that is a broker-dealer, but only with respect to Exchange Securities received by such broker-dealer pursuant to an Exchange Offer in exchange for Registrable Securities acquired by the broker-dealer directly from
the Company. 
 “Rule 144,” “Rule 405” and “Rule 415” shall mean, in each case, such rule
promulgated under the Securities Act (or any successor provision), as the same shall be amended from time to time. 
 “Securities” shall mean approximately $925,000,000 in aggregate principal amount of the Company’s 8 7/8% Senior Secured Notes due 2019, and securities issued in exchange therefor or in lieu thereof pursuant to the Indenture. Each Security is entitled to the benefit of the guarantees provided for in the Indenture (the
“Guarantees”) and, unless the context otherwise requires, any reference herein to a “Security,” an “Exchange Security” or a “Registrable Security” shall include a reference to the related Guarantees.

 “Securities Act” shall mean the Securities Act of 1933, or any successor thereto, as the same shall be amended
from time to time. 
 “Special Interest” shall have the meaning assigned thereto in Section 2(b) hereof. 
 “Trustee” shall mean The Bank of New York Mellon Trust Company, N.A., as trustee under the Indenture, together with any successors in
such capacity. 
  

 3 

 “Trust Indenture Act” shall mean the Trust Indenture Act of 1939, or any successor
thereto, and the rules, regulations and forms promulgated thereunder, all as the same shall be amended from time to time. 
 Unless the
context otherwise requires, any reference herein to a “Section” or “clause” refers to a Section or clause, as the case may be, of this Agreement, and the words “herein,” “hereof” and “hereunder” and
other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. 
 2.
Registration Under the Securities Act. 
 (a) Subject to the last sentence of this Section 2(a), if the Securities
have not become Freely Tradable on or before the Free Trade Date, the Company and the Guarantors agree to use all commercially reasonable efforts to (i) file under the Securities Act a registration statement relating to an offer to exchange
(such registration statement, the “Exchange Registration Statement,” and such offer, the “Exchange Offer”) any and all of the Securities for a like aggregate principal amount of debt securities issued by the Company
and guaranteed by the Guarantors, which debt securities and guarantees are substantially identical to the Securities and the related Guarantees, respectively (and are entitled to the benefits of a trust indenture that is substantially identical to
the Indenture or is the Indenture and that has been qualified under the Trust Indenture Act), except that they have been registered pursuant to an effective registration statement under the Securities Act and do not contain provisions for the
additional interest contemplated in Section 2(b) below (such new debt securities are hereinafter called “Exchange Securities”), (ii) cause the Exchange Registration Statement to become effective under the Securities Act,
(iii) commence the Exchange Offer promptly after such Exchange Registration Statement has become effective, (iv) hold the Exchange Offer open for at least 20 Business Days (or longer if required by applicable law) after the date that
notice of the Exchange Offer is mailed to holders of the Securities, (v) exchange Exchange Securities for all Registrable Securities that have been properly tendered and not withdrawn on or prior to the expiration of the Exchange Offer and
(vi) consummate the Exchange Offer on the earliest practicable date after the Exchange Registration Statement has become affected, but in no event later than 30 Business Days thereafter (such 30th Business Day being the “Consummation
Date”). The Exchange Offer will be registered under the Securities Act on the appropriate form and will comply with all applicable tender offer rules and regulations under the Exchange Act. The Exchange Offer will be deemed to have been
“completed” only if the debt securities and related guarantees received by holders other than Restricted Holders in the Exchange Offer for Registrable Securities are, upon receipt, transferable by each such holder without restriction under
the Securities Act and the Exchange Act and without material restrictions under the blue sky or securities laws of a substantial majority of the states of the United States of America. The Exchange Offer shall be deemed to have been completed upon
the earlier to occur of (A) the Company having exchanged the Exchange Securities for all outstanding Registrable Securities pursuant to the Exchange Offer and (B) the Company having exchanged, pursuant to the Exchange Offer, Exchange
Securities for all Registrable Securities that have been properly tendered and not withdrawn before the expiration of the Exchange Offer, which shall be on a date that is at least 20 Business Days following the commencement of the Exchange Offer.
The Company and the Guarantors agree (I) to include in the Exchange Registration Statement a prospectus for use in any resales by any holder of Exchange Securities that is a broker-dealer and (II) to keep such Exchange Registration Statement
effective for a period (the “Resale Period”) beginning when Exchange Securities are first issued in the Exchange Offer and ending upon the earlier of the expiration of the 180th day after the Exchange Offer has been completed or
such time as such broker-dealers no longer own any Registrable Securities. With respect to such Exchange Registration Statement, such holders shall have the benefit of the rights of indemnification and contribution set forth in Sections 6(a), (b),
(c) and (d) hereof. The obligations of the Company and the Guarantors set forth in this Section 2(a) shall cease on the date on which the Securities become Freely Tradable. 
  

 4 

 (b) If (i) the Exchange Offer has not been consummated prior to the Consummation
Date, (ii) the Securities have not become Freely Tradable on or before the Free Trade Date, or (iii) any Exchange Registration Statement required by this Agreement is filed and declared effective, but shall thereafter cease to be effective
or fail to be usable for its intended purpose without being succeeded by a post-effective amendment or prospectus supplement to such Exchange Registration Statement that cures such failure and that is itself declared effectively promptly (each such
event referred to in clauses (i) through (iii), a “Registration Default,” and the period during which a Registration Default has occurred and is continuing, the “Registration Default Period”), then, as
liquidated damages for such Registration Default, subject to the provisions of Section 8(b), special interest (“Special Interest”), in addition to the Base Interest, shall accrue at a per annum rate of 0.25% for the first 90
days of the Registration Default Period, at a per annum rate of 0.50% for the second 90 days of the Registration Default Period, at a per annum rate of 0.75% for the third 90 days of the Registration Default Period and at a per annum rate of 1.0%
thereafter for the remaining portion of the Registration Default Period, provided that in no event shall the Company be required to pay Special Interest for more than one Registration Default at any given time. The Registration Default Period shall
terminate on the date on which (i) the Securities become Freely Tradable or (ii) the Exchange Registration Statement has been declared effective and the Exchange Offer has been consummated. 
 (c) The Company shall take, and shall cause the Guarantors to take, all actions necessary or advisable to be taken to ensure that the
transactions contemplated herein are effected as so contemplated, including all actions necessary or desirable to register the Guarantees under the Exchange Registration Statement contemplated in Section 2(a) hereof. 
 (d) Any reference herein to a registration statement as of any time shall be deemed to include any document incorporated, or deemed to be
incorporated, therein by reference as of such time and any reference herein to any post-effective amendment to a registration statement as of any time shall be deemed to include any document incorporated, or deemed to be incorporated, therein by
reference as of such time. 
 3. Registration Procedures. 
 If the Company and the Guarantors file a registration statement pursuant to Section 2(a), the following provisions shall apply: 
 (a) At or before the Effective Time of the Exchange Registration, the Company and the Guarantors shall qualify the Indenture under the
Trust Indenture Act. 
 (b) In the event that such qualification would require the appointment of a new trustee under the
Indenture, the Company and the Guarantors shall appoint a new trustee thereunder pursuant to the applicable provisions of the Indenture. 
 (c) In connection with the Company’s and the Guarantors’ obligations with respect to the registration of Exchange Securities as contemplated by Section 2(a) (the “Exchange
Registration”), if applicable, the Company and the Guarantors shall, as soon as practicable (or as otherwise specified): 
 (i) prepare and file with the Commission an Exchange Registration Statement on any form that may be utilized by the Company and the Guarantors and that shall permit the Exchange Offer and resales of Exchange Securities by broker-dealers
during the Resale Period to be effected as contemplated by Section 2(a), and use all commercially reasonable efforts to cause such Exchange Registration Statement to become effective; 
 (ii) prepare and file with the Commission such amendments and supplements to such Exchange Registration Statement and the prospectus
included therein as may be necessary to 

  

 5 

 
effect and maintain the effectiveness of such Exchange Registration Statement for the periods and purposes contemplated in Section 2(a) hereof and as
may be required by the applicable rules and regulations of the Commission and the instructions applicable to the form of such Exchange Registration Statement, and promptly provide each broker-dealer holding Exchange Securities with such number of
copies of the prospectus included therein (as then amended or supplemented), in conformity in all material respects with the requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder,
as such broker-dealer reasonably may request prior to the expiration of the Resale Period, for use in connection with resales of Exchange Securities; 
 (iii) notify each broker-dealer that has requested or received copies of the prospectus included in such Exchange Registration Statement, and confirm such advice in writing, (A) when such Exchange Registration
Statement or the prospectus included therein or any prospectus amendment or supplement or post-effective amendment has been filed, and, with respect to such Exchange Registration Statement or any post-effective amendment, when the same has become
effective, (B) of any comments by the Commission and by the blue sky or securities commissioner or regulator of any state with respect thereto or any request by the Commission for amendments or supplements to such Exchange Registration
Statement or prospectus or for additional information, (C) of the issuance by the Commission of any stop order suspending the effectiveness of such Exchange Registration Statement or the initiation or threatening of any proceedings for that
purpose, (D) if at any time the representations and warranties of the Company and the Guarantors contemplated by Section 5 cease to be true and correct in all material respects, (E) of the receipt by the Company of any notification
with respect to the suspension of the qualification of the Exchange Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, or (F) at any time during the Resale Period when a prospectus is
required to be delivered under the Securities Act, that such Exchange Registration Statement, prospectus, prospectus amendment or supplement or post-effective amendment does not conform in all material respects to the applicable requirements of the
Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder or contains an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances then existing; 
 (iv) in the event that the Company and the
Guarantors would be required, pursuant to Section 3(c)(iii)(F) above, to notify any broker-dealers holding Exchange Securities, prepare and furnish to each such holder a reasonable number of copies of a prospectus supplemented or amended so
that, as thereafter delivered to purchasers of such Exchange Securities during the Resale Period, such prospectus shall conform in all material respects to the applicable requirements of the Securities Act and the Trust Indenture Act and the rules
and regulations of the Commission thereunder and shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing; 
 (v) use all commercially reasonable efforts to obtain the withdrawal of any order suspending
the effectiveness of such Exchange Registration Statement or any post-effective amendment thereto at the earliest practicable date; 
 (vi) use all commercially reasonable efforts to (A) register or qualify the Exchange Securities under the securities laws or blue sky laws of such jurisdictions as are contemplated by Section 2(a) no later than the commencement of
the Exchange Offer, (B) keep such registrations or qualifications in effect and comply with such laws so as to permit the continuance of offers, sales and dealings therein in such jurisdictions until the expiration of the Resale Period and
(C) take any and all other actions as may be reasonably necessary or 

  

 6 

 
advisable to enable each broker-dealer holding Exchange Securities to consummate the disposition thereof in such jurisdictions; provided, however,
that neither the Company nor any of the Guarantors shall be required for any such purpose to (1) qualify as a foreign corporation in any jurisdiction wherein it would not otherwise be required to qualify but for the requirements of this
Section 3(c)(vi), (2) consent to general service of process in any such jurisdiction or (3) in the case of the Company, make any changes to its certificate of incorporation or bylaws or any agreement between it and its stockholders,
and in the case of the Guarantors, make any changes to (x) the certificate (or articles) of incorporation, certificate (or articles) of organization, certificate (or articles) of formation or certificate of limited partnership, as the case may
be, and any amendments thereto, of any Guarantor, (y) the bylaws, limited liability company agreement, operating agreement or partnership agreement, as the case may be, and any amendments thereto, of any Guarantor or (z) any agreement
between any Guarantor and its stockholders, shareholders, members or partners; 
 (vii) use all commercially reasonable
efforts to obtain the consent or approval of each governmental agency or authority, whether federal, state or local, that may be required to effect the Exchange Registration, the Exchange Offer and the offering and sale of Exchange Securities by
broker-dealers during the Resale Period; 
 (viii) provide a CUSIP number for all Exchange Securities, not later than the
applicable Effective Time; and 
 (ix) comply with all applicable rules and regulations of the Commission, and make generally
available to its securityholders as soon as practicable but no later than 18 months after the Effective Time of such Exchange Registration Statement, an earnings statement of the Company and its subsidiaries complying with Section 11(a) of the
Securities Act (including, at the option of the Company, Rule 158 thereunder). 
 (d) Until the expiration of one year after
the Closing Date, the Company and the Guarantors will not, and will not permit any of their “affiliates” (as defined in Rule 144) to, resell any of the Securities that have been reacquired by any of them except pursuant to an effective
registration statement under the Securities Act. 
 4. Registration Expenses. 
 The Company and the Guarantors agree to bear and to pay or cause to be paid promptly all expenses incident to the Company’s and the Guarantors’
performance of or compliance with this Agreement, including (a) all Commission and any FINRA registration, filing and review fees and expenses including fees and disbursements of counsel for the placement or sales agent or underwriters in
connection with such registration, filing and review; (b) all expenses relating to the preparation, printing, production, distribution and reproduction of each registration statement required to be filed hereunder, each prospectus included
therein or prepared for distribution pursuant hereto, each amendment or supplement to the foregoing, the expenses of preparing the Securities for delivery and the expenses of printing or producing any blue sky or legal investment memoranda and all
other documents in connection with the offering, sale or delivery of Securities to be disposed of (including certificates representing the Securities); (c) messenger, telephone and delivery expenses relating to the offering, sale or delivery of
Securities and the preparation of documents referred in clause (b) above; (d) fees and expenses of the Trustee under the Indenture, any agent of the Trustee and any counsel for the Trustee and of any collateral agent or custodian;
(e) internal expenses (including all salaries and expenses of the Company’s or Guarantors’ officers and employees performing legal or accounting duties); (f) fees, disbursements and expenses of counsel and independent certified
public accountants of the Company (including the expenses of any opinions or “cold comfort” letters required by or incident to such performance and compliance); (g) any fees charged by securities rating services for rating the
Securities; and (h) fees, expenses and 

  

 7 

 
disbursements of any other persons, including special experts, retained by the Company or its Guarantors in connection with this Agreement (collectively, the
“Registration Expenses”). To the extent that any reasonable fees are incurred, assumed or paid by any holder of Registrable Securities or its counsel, the Company or its Guarantors shall reimburse such person for the full amount of
such reasonable fees so incurred, assumed or paid promptly after receipt of a request therefor. Notwithstanding the foregoing, the holders of the Registrable Securities being registered shall pay all agency fees and commissions attributable to the
sale of such Registrable Securities. 
 5. Representations and Warranties. 
 The Company and each of the Guarantors represents and warrants to, and agrees with, the Initial Purchasers and each of the holders from time to time of
Registrable Securities that: 
 (a) Each registration statement covering Registrable Securities and each prospectus (including
any preliminary or summary prospectus) contained therein or furnished pursuant to Section 3(c) hereof and any further amendments or supplements to any such registration statement or prospectus, when it becomes effective or is filed with the
Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder and will not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; and at all times subsequent to the Effective Time when a prospectus would be required to be delivered under the
Securities Act, other than from (i) such time as a notice has been given to holders of Registrable Securities pursuant to Section 3(c)(iii)(F) hereof until (ii) such time as the Company furnishes an amended or supplemented prospectus
pursuant to Section 3(c)(iv) hereof, each such registration statement, and each prospectus (including any summary prospectus) contained therein or furnished pursuant to Section 3(c) hereof, as then amended or supplemented, will conform in
all material respects to the requirements of the Securities Act and the Trust Indenture Act and the rules and regulations of the Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; provided, however, that this representation and warranty shall not apply to any statements or omissions
made in reliance upon and in conformity with information furnished in writing to the Company by a holder of Registrable Securities expressly for use therein. 
 (b) Any documents incorporated by reference in any prospectus referred to in Section 5(a) hereof, when they become or became
effective or are or were filed with the Commission, as the case may be, will conform or conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and none of such documents will contain or
contained an untrue statement of a material fact or will omit or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and
warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by a holder of Registrable Securities expressly for use therein. 
 (c) The compliance by the Company and the Guarantors with all of the provisions of this Agreement and the consummation of the transactions
herein contemplated will not conflict with or result in a material breach of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company or any subsidiary of the Company is a party or by which the Company or any subsidiary of the Company is bound or to which any of the property or assets of the Company or any subsidiary of the Company is subject, nor will such action result
in any violation of the provisions of the articles of incorporation, as amended, or the bylaws of the Company; the certificate (or articles) of incorporation, certificate (or articles) of organization, certificate (or articles) of formation or

  

 8 

 
certificate of limited partnership, as the case may be, and any amendments thereto, of any Guarantor; the bylaws, limited liability company agreement,
operating agreement or partnership agreement, as the case may be, and any amendments thereto, of any Guarantor; or any material violation of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction
over the Company or any subsidiary of the Company or any of their properties; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the consummation by
the Company and the Guarantors of the transactions contemplated by this Agreement, except the registration under the Securities Act of the Securities, qualification of the Indenture under the Trust Indenture Act and such consents, approvals,
authorizations, registrations or qualifications as may be required under State securities or blue sky laws in connection with the offering and distribution of the Securities. 
 (d) This Agreement has been duly authorized, executed and delivered by the Company and each Guarantor. 
 6. Indemnification. 
 (a) Indemnification by the Company and the Guarantors. The Company and the Guarantors, jointly and severally, will indemnify and hold harmless each of the holders of Registrable Securities included in an Exchange Registration
Statement, and each person who participates as a placement or sales agent or as an underwriter in any offering or sale of such Registrable Securities against any losses, claims, damages or liabilities, joint or several, to which such holder, agent
or underwriter may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a
material fact contained in any Exchange Registration Statement under which such Registrable Securities were registered under the Securities Act, or any preliminary, final or summary prospectus contained therein or furnished by the Company to any
such holder, agent or underwriter, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, and will reimburse such holder, such agent and such underwriter for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such action or claim as such expenses are incurred;
provided, however, that neither the Company nor any Guarantor shall be liable to any such person in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission made in any registration statement contemplated hereunder, or preliminary, final or summary prospectus, or amendment or supplement thereto, in reliance upon and in conformity with written information
furnished to the Company by such person expressly for use therein. 
 (b) Notices of Claims, Etc. Promptly after
receipt by an indemnified party under subsection (a) above of written notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party pursuant to the
indemnification provisions of or contemplated by this Section 6, notify such indemnifying party in writing of the commencement of such action; but the omission so to notify the indemnifying party shall not relieve it from any liability which it
may have to any indemnified party otherwise than under the indemnification provisions of or contemplated by Section 6(a) hereof. In case any such action shall be brought against any indemnified party and it shall notify an indemnifying party of
the commencement thereof, such indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the
defense thereof, such indemnifying party shall not be liable to such indemnified party for any legal expenses of other counsel or any other 

  

 9 

 
expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation.
No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which
indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the
indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
 (c) Contribution. If for any reason the indemnification provisions contemplated by Section 6(a) are unavailable to or
insufficient to hold harmless an indemnified party in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party in connection with
the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified party
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such indemnifying party or by such
indemnified party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contributions pursuant
to this Section 6(c) were determined by pro rata allocation (even if the holders or any agents or underwriters or all of them were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in this Section 6(c). The amount paid or payable by an indemnified party as a result of the losses, claims, damages, or liabilities (or actions in respect thereof) referred to above shall be deemed to
include any legal or other fees or expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 6(c), no holder shall be required
to contribute any amount in excess of the amount by which the dollar amount of the proceeds received by such holder from the sale of any Registrable Securities (after deducting any fees, discounts and commissions applicable thereto) exceeds the
amount of any damages that such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, and no underwriter shall be required to contribute any amount in excess of the amount by
which the total price at which the Registrable Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation. The holders’ obligations in this Section 6(c) to contribute shall be several in proportion to the principal amount of Registrable Securities registered by them and not joint. 
 (d) The obligations of the Company and the Guarantors under this Section 6 shall be in addition to any liability which the Company or
the Guarantors may otherwise have and shall extend, upon the same terms and conditions, to each officer, director and partner of each holder, agent and underwriter and each person, if any, who controls any holder, agent or underwriter within the
meaning of the Securities Act; and the obligations of the holders and any agents or underwriters contemplated by this Section 6 shall be in addition to any liability which the respective holder, agent or underwriter may otherwise have and shall
extend, upon the same terms and conditions, to each officer and director of the Company or any Guarantor (including any person who, with his consent, is named in any registration statement as about to become a director of the Company or any
Guarantor) and to each person, if any, who controls the Company within the meaning of the Securities Act. 
  

 10 

 7. Rule 144. 
 The Company covenants to the holders of Registrable Securities that to the extent it shall be required to do so under the Exchange Act, the Company shall timely file the reports required to be filed by it under the
Exchange Act or the Securities Act (including the reports under Section 13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1) of Rule 144 adopted by the Commission under the Securities Act) and the rules and regulations adopted by
the Commission thereunder, and shall take such further action as any holder of Registrable Securities may reasonably request, all to the extent required from time to time to enable such holder to sell Registrable Securities without registration
under the Securities Act within the limitations of the exemption provided by Rule 144 under the Securities Act, as such Rule may be amended from time to time, or any similar or successor rule or regulation hereafter adopted by the Commission. Upon
the request of any holder of Registrable Securities in connection with that holder’s sale pursuant to Rule 144, the Company shall deliver to such holder a written statement as to whether it has complied with such requirements. 
 8. Miscellaneous. 
 (a) No Inconsistent Agreements. The Company and each Guarantor represents, warrants, covenants and agrees that it has not granted, and shall not grant, registration rights with respect to Registrable Securities or any other
securities which would be inconsistent with the terms contained in this Agreement. 
 (b) Specific Performance. The
parties hereto acknowledge that there would be no adequate remedy at law if the Company or any Guarantor fails to perform any of its obligations hereunder and that the Initial Purchasers and the holders from time to time of the Registrable
Securities may be irreparably harmed by any such failure, and accordingly agree that the Initial Purchasers and such holders, in addition to any other remedy to which they may be entitled at law or in equity, shall be entitled to seek specific
performance of the obligations of the Company and the Guarantors under this Agreement in accordance with the terms and conditions of this Agreement, in any court of the United States or any state thereof having jurisdiction. 
 (c) Notices. All notices, requests, claims, demands, waivers and other communications hereunder shall be in writing and shall be
deemed to have been duly given when delivered by hand, if delivered personally or by courier, or three days after being deposited in the mail (registered or certified mail, postage prepaid, return receipt requested) as follows: If to the Company, to
it at 13737 Noel Road, Dallas, Texas 75240, Attention: Chief Financial Officer, and if to a holder, to the address of such holder set forth in the security register or other records of the Company, or to such other address as the Company or any such
holder may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 
 (d) Parties in Interest. All the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall be enforceable by the parties hereto and the holders from time to time of
the Registrable Securities and the respective successors and assigns of the parties hereto and such holders. In the event that any transferee of any holder of Registrable Securities shall acquire Registrable Securities, in any manner, whether by
gift, bequest, purchase, operation of law or otherwise, such transferee shall, without any further writing or action of any kind, be deemed a beneficiary hereof for all purposes and such Registrable Securities shall be held subject to all of the
terms of this Agreement, and by taking and holding such Registrable Securities such transferee shall be entitled to receive the benefits of, and be conclusively deemed to have agreed to be bound by all of the applicable terms and provisions of this
Agreement. If the Company shall so request, any such successor, assign or transferee shall agree in writing to acquire and hold the Registrable Securities subject to all of the applicable terms hereof. 
  

 11 

 (e) Survival. The respective indemnities, agreements, representations, warranties
and each other provision set forth in this Agreement or made pursuant hereto shall remain in full force and effect regardless of any investigation (or statement as to the results thereof) made by or on behalf of any holder of Registrable Securities,
any director, officer or partner of such holder, any agent or underwriter or any director, officer or partner thereof, or any controlling person of any of the foregoing, and shall survive delivery of and payment for the Registrable Securities
pursuant to the Purchase Agreement and the transfer and registration of Registrable Securities by such holder and the consummation of an Exchange Offer. 
 (f) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 
 (g) Headings. The descriptive headings of the several sections and paragraphs of this Agreement are inserted for convenience only,
do not constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. 
 (h) Entire Agreement; Amendments. This Agreement and the other writings referred to herein (including the Indenture, the Purchase Agreement and the form of Securities) or delivered pursuant hereto which form a part hereof contain the
entire understanding of the parties with respect to its subject matter. This Agreement supersedes all prior agreements and understandings between the parties with respect to its subject matter. This Agreement may be amended and the observance of any
term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument duly executed by the Company, the Guarantors and the holders of at least a majority in
aggregate principal amount of the Registrable Securities at the time outstanding. Each holder of any Registrable Securities at the time or thereafter outstanding shall be bound by any amendment or waiver effected pursuant to this Section 8(h),
whether or not any notice, writing or marking indicating such amendment or waiver appears on such Registrable Securities or is delivered to such holder. 
 (i) Inspection. For so long as this Agreement shall be in effect, this Agreement and a complete list of the names and addresses of all the holders of Registrable Securities shall be made available for
inspection and copying on any Business Day by any holder of Registrable Securities for proper purposes only (which shall include any purpose related to the rights of the holders of Registrable Securities under the Securities, the Indenture and this
Agreement) at the offices of the Company at the address thereof set forth in Section 8(c) above and at the office of the Trustee under the Indenture. 
 (j) Counterparts. This Agreement may be executed by the parties in counterparts, each of which shall be deemed to be an original, but all such respective counterparts shall together constitute one and the same
instrument. 
 (signature pages follow) 
  

 12 

 If the foregoing is in accordance with your understanding, please sign and return to us two counterparts
hereof, and upon the acceptance hereof by you, on behalf of each of the holders, this letter and such acceptance hereof shall constitute a binding agreement among each of the holders, the Guarantors and the Company. 
  

			
	Very truly yours,
	
	TENET HEALTHCARE CORPORATION
		
	By:	 	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Chief Financial Officer

 (SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT) 

			
	CORAL GABLES HOSPITAL, INC., as:
	General Partner of CGH HOSPITAL, LTD.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	TENET PHYSICIAN SERVICES—HILTON HEAD, INC., as:
	General Partner of HILTON HEAD HEALTH SYSTEM, L.P.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	CYPRESS FAIRBANKS MEDICAL CENTER, INC., as:
	General Partner of NEW MEDICAL HORIZONS II, LTD.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	TENET LOUISIANA, INC., as:
	Sole and Managing Member of NORTHSHORE REGIONAL MEDICAL CENTER, L.L.C.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	TENET TEXAS, INC., as:
	General Partner of TENET FRISCO, LTD.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer

 (SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT) 

			
	TENET HEALTHSYSTEM PHILADELPHIA, INC., as:
	Managing Member of TENET HEALTHSYSTEM HAHNEMANN, LLC
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	TENET HEALTHSYSTEM PHILADELPHIA, INC., as:
	Managing Member of TENET HEALTHSYSTEM
	ST. CHRISTOPHER’S HOSPITAL FOR CHILDREN, L.L.C.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	TENET TEXAS, INC., as:
	General Partner of TENET HOSPITALS LIMITED
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	LIFEMARK HOSPITALS, INC., as:
	General Partner of TH HEALTHCARE, LTD.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer
	
	AMERICAN MEDICAL (CENTRAL), INC.
	AMI INFORMATION SYSTEMS GROUP, INC.
	AMISUB (HEIGHTS), INC.
	AMISUB (HILTON HEAD), INC.
	AMISUB (SFH), INC.
	AMISUB (TWELVE OAKS), INC.
	AMISUB OF NORTH CAROLINA, INC.
	AMISUB OF SOUTH CAROLINA, INC.
	AMISUB OF TEXAS, INC.
	BROOKWOOD HEALTH SERVICES, INC.
	COASTAL CAROLINA MEDICAL CENTER, INC.
	COMMUNITY HOSPITAL OF LOS GATOS, INC.
	CORAL GABLES HOSPITAL, INC.

 (SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT) 

			
	CYPRESS FAIRBANKS MEDICAL CENTER, INC.
	DELRAY MEDICAL CENTER, INC.
	DOCTORS HOSPITAL OF MANTECA, INC.
	DOCTORS MEDICAL CENTER OF MODESTO, INC.
	EAST COOPER COMMUNITY HOSPITAL, INC.
	FMC MEDICAL, INC.
	FOUNTAIN VALLEY REGIONAL HOSPITAL AND MEDICAL CENTER
	FRYE REGIONAL MEDICAL CENTER, INC.
	JFK MEMORIAL HOSPITAL, INC.
	LAKEWOOD REGIONAL MEDICAL CENTER, INC.
	LIFEMARK HOSPITALS OF FLORIDA, INC.
	LIFEMARK HOSPITALS, INC.
	LOS ALAMITOS MEDICAL CENTER, INC.
	NORTH FULTON MEDICAL CENTER, INC.
	ORNDA HOSPITAL CORPORATION
	PALM BEACH GARDENS COMMUNITY HOSPITAL, INC.
	PLACENTIA-LINDA HOSPITAL, INC.
	SAN RAMON REGIONAL MEDICAL CENTER, INC.
	SIERRA VISTA HOSPITAL, INC.
	TENET 1500 SAN PABLO, INC.
	TENET CALIFORNIA, INC.
	TENET FLORIDA, INC.
	TENET GOOD SAMARITAN, INC.
	TENET HEALTHSYSTEM BARTLETT, INC.
	TENET HEALTHSYSTEM CFMC, INC.
	TENET HEALTHSYSTEM DESERT, INC.
	TENET HEALTHSYSTEM DI, INC.
	TENET HEALTHSYSTEM GB, INC.
	TENET HEALTHSYSTEM HEALTHCORP
	TENET HEALTHSYSTEM HOLDINGS, INC.
	TENET HEALTHSYSTEM KNC, INC.
	TENET HEALTHSYSTEM MEDICAL, INC.
	TENET HEALTHSYSTEM NORTH SHORE, INC.
	TENET HEALTHSYSTEM PHILADELPHIA, INC.
	TENET HEALTHSYSTEM SGH, INC.
	TENET HEALTHSYSTEM SL, INC.
	TENET HEALTHSYSTEM SPALDING, INC.
	TENET HIALEAH HEALTHSYSTEM, INC.
	TENET HOSPITALS, INC.
	TENET LOUISIANA, INC.
	TENET MISSOURI, INC.
	TENET PHYSICIAN SERVICES—HILTON HEAD, INC.
	TENET SOUTH FULTON, INC.
	TENET ST. MARY’S, INC.
	TENET TEXAS, INC.
	TENETSUB TEXAS, INC.
	TWIN CITIES COMMUNITY HOSPITAL, INC.
	WEST BOCA MEDICAL CENTER, INC.
	
	 /s/ Biggs C. Porter

	Name:	 	Biggs C. Porter
	Title:	 	Treasurer

 (SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT) 

			
	The foregoing Agreement is hereby confirmed and accepted as of the date first above written.
	
	 BANC OF AMERICA SECURITIES LLC
 (on behalf of the holders)

		
	 By:
	 	 /s/ Peter Almond

	 Name:
	 	Peter Almond
	 Title:
	 	Vice President
	
	 GOLDMAN, SACHS & CO.
 (on
behalf of the holders)

		
	 By:
	 	 /s/ Goldman Sachs & Co.

		 	Goldman Sachs & Co.
		 	
	
	 CITIGROUP GLOBAL MARKETS INC.
 (on behalf of the holders)

		
	 By:
	 	 /s/ Stuart G. Dickson

	 Name:
	 	Stuart G. Dickson
	 Title:
	 	Director
	
	 SCOTIA CAPITAL (USA) INC.
 (on behalf of the holders)

		
	 By:
	 	 /s/ Greg Greer

	 Name:
	 	Greg Greer
	 Title:
	 	Managing Director
	
	 BARCLAYS CAPITAL INC.
 (on behalf of the holders)

		
	 By:
	 	  
 /s/ John Skrobe

	 Name:
	 	John Skrobe
	 Title:
	 	Managing Director
	
	 CREDIT SUISSE SECURITIES (USA) LLC
 (on behalf of the holders)

		
	 By:
	 	 /s/ Steven Schwartz

	 Name:
	 	Steven Schwartz
	 Title:
	 	Managing Director
	
	 WACHOVIA CAPITAL MARKETS, LLC
 (on behalf of the holders)

		
	 By:
	 	 /s/ David Gillespie

	 Name:
	 	David Gillespie
	 Title:
	 	Managing Director

 (SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT) 

 Schedule I 
 Guarantors 
 American Medical (Central), Inc. 
 AMI Information Systems Group, Inc. 
 Amisub (Heights), Inc. 
 Amisub (Hilton Head), Inc. 
 Amisub (SFH), Inc. 
 Amisub (Twelve Oaks), Inc. 
 Amisub of North Carolina, Inc. 
 Amisub of South Carolina, Inc. 
 Amisub of Texas, Inc. 
 Brookwood Health Services, Inc. 
 CGH Hospital, Ltd. 
 Coastal Carolina Medical Center, Inc. 
 Community Hospital of Los Gatos, Inc. 
 Coral Gables Hospital, Inc. 
 Cypress Fairbanks Medical Center, Inc.

 Delray Medical Center, Inc. 
 Doctors Hospital of Manteca, Inc.

 Doctors Medical Center of Modesto, Inc. 
 East Cooper Community
Hospital, Inc. 
 FMC Medical, Inc. 
 Fountain Valley Regional
Hospital and Medical Center 
 Frye Regional Medical Center, Inc. 
 Hilton Head Health System, L.P. 
 JFK Memorial Hospital, Inc. 
 Lakewood Regional Medical Center, Inc. 
 Lifemark Hospitals of Florida, Inc. 
 Lifemark Hospitals, Inc. 
 Los Alamitos Medical Center, Inc. 
 New Medical Horizons II, Ltd. 
 North Fulton Medical Center, Inc. 
 NorthShore Regional Medical Center, L.L.C. 
 OrNda Hospital Corporation

 Palm Beach Gardens Community Hospital, Inc. 
 Placentia-Linda
Hospital, Inc. 
 San Ramon Regional Medical Center, Inc. 
 Sierra
Vista Hospital, Inc. 
 Tenet 1500 San Pablo, Inc. 
 Tenet
California, Inc. 
 Tenet Florida, Inc. 
 Tenet Frisco, Ltd.

 Tenet Good Samaritan, Inc. 
 Tenet HealthSystem Bartlett, Inc.

 Tenet HealthSystem CFMC, Inc. 
 Tenet HealthSystem Desert, Inc.

 Tenet HealthSystem DI, Inc. 
 Tenet HealthSystem GB, Inc.

 Tenet HealthSystem Hahnemann, LLC 
 Tenet HealthSystem
HealthCorp 

 Tenet HealthSystem Holdings, Inc. 
 Tenet HealthSystem KNC, Inc. 
 Tenet HealthSystem Medical, Inc. 
 Tenet HealthSystem North Shore, Inc. 
 Tenet HealthSystem Philadelphia, Inc. 
 Tenet HealthSystem SGH, Inc. 
 Tenet HealthSystem SL, Inc. 
 Tenet HealthSystem Spalding, Inc. 
 Tenet HealthSystem St. Christopher’s Hospital for Children, L.L.C. 
 Tenet Hialeah HealthSystem, Inc. 
 Tenet Hospitals, Inc. 
 Tenet Hospitals Limited 
 Tenet Louisiana, Inc. 
 Tenet Missouri, Inc. 
 Tenet Physician Services—Hilton Head, Inc.

 Tenet South Fulton, Inc. 
 Tenet St. Mary’s, Inc.

 Tenet Texas, Inc. 
 Tenetsub Texas, Inc. 
 TH Healthcare, Ltd. 
 Twin Cities Community Hospital, Inc. 
 West Boca Medical Center, Inc.Consulting Agreement

 Exhibit 10.1 
 MEDICINOVA, INC. 
 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (“Agreement”) is made by and between MediciNova, Inc., a Delaware
corporation (“MediciNova”), and Danerius, LLC, a Delaware limited liability company (“Consultant”), effective as of June 12, 2009 (“Effective Date”), for the purpose of setting forth the terms and conditions by
which MediciNova will acquire Consultant’s services. 
 In consideration of the mutual obligations specified in this Agreement, and any
compensation paid to Consultant for his or her services, the parties agree to the following: 
 1. Services. Attached to this
Agreement as Exhibit A and incorporated herein by this reference is a statement of the work to be performed by Consultant (“Services”), the payment terms for the Services, the types of any expenses to be paid in connection with the
Services, a description of the deliverables to be provided by Consultant and such other terms and conditions as the parties deem appropriate or necessary for the performance of the Services (“Statement of Work”). Consultant shall perform
all Services set forth herein in a timely and professional manner consistent with professional standards and in accordance with the terms and conditions of this Agreement, including Exhibit A. The parties agree that all Services shall be
performed by Alan W. Dunton, the principal of Consultant; provided, however, that Consultant may engage the assistance of other persons with the prior written consent of MediciNova. 
 2. Compensation; Payments. 
 2.1
Compensation. In consideration of the Services to be rendered hereunder, Consultant shall be paid as set forth in the Statement of Work. Unless otherwise set forth in the Statement of Work, any payments due to Consultant for performance of the
Services, except with respect to amounts subject to a bona fide dispute, shall be due thirty (30) days from receipt by MediciNova of Consultant’s invoice therefor. 
 2.2 Expenses. MediciNova shall reimburse Consultant for reasonable travel and other business expenses that are incurred by Consultant in the
performance of the Services and are approved in advance by MediciNova. Consultant shall provide MediciNova with an itemized list of all such expenses and supporting receipts with each invoice therefor. 
 3. Proprietary Information. 
 3.1
Proprietary Information. In the course of performing the Services hereunder, Consultant understands that he will receive and otherwise be exposed to confidential and proprietary information, materials and know-how owned by MediciNova or received
by MediciNova from third parties pursuant to an obligation of confidentiality with respect thereto which relate to MediciNova’s product development programs, business and operations, strategies, technologies, intellectual property and potential
business transactions in whatever form, tangible or intangible, whether disclosed to or learned by Consultant before or after the Effective Date of this Agreement (“Proprietary Information”). For purposes of this Agreement, Proprietary
Information shall include, but not be limited to, (a) any compound, formulation or sample; (b) any procedure, discovery, invention, formula, data, result, idea or technique; (c) any trade secret, trade dress, copyright, patent or
other intellectual property right, or any registration or application 

 
therefor, or materials relating thereto; (d) any information relating to any of the foregoing or to any research, development, manufacturing,
engineering, marketing, servicing, sales, financing, strategic acquisitions or business combinations, legal or other business activities of MediciNova or to any of MediciNova’s present or future products, pricing, plans, forecasts, suppliers,
clients, customers, employees, consultants, partners or investors; (e) all personal property, including, without limitation, all books, manuals, records, reports, notes, contracts, lists, blueprints and other documents or materials, or copies
thereof, received by Consultant in the course of Consultant’s performance of the Services, including records and other materials pertaining to Work Product (as defined below); and (f) all Work Product. In addition, the terms and conditions
of this Agreement and the fact that Consultant is performing the Services on behalf of MediciNova shall be deemed Proprietary Information hereunder. 
 3.2 Restrictions on Use and Disclosure. Consultant acknowledges the confidential and secret nature of the Proprietary Information and agrees that the Proprietary Information is the extremely valuable property
of MediciNova or of the third party from which MediciNova received such Proprietary Information. Accordingly, Consultant agrees that, during the term of this Agreement and thereafter, he (a) shall hold all Proprietary Information in strict
confidence for the benefit of MediciNova; (b) shall not copy or use any Proprietary Information, except as may be necessary to perform the Services; (c) shall use the Proprietary Information only for the benefit of MediciNova in
performance of the Services hereunder (and not for the benefit of Consultant or any third party or for any other purpose); and (d) shall not disclose or otherwise make available any such Proprietary Information to any third party, except as
authorized in writing and in advance by MediciNova. All Proprietary Information is and shall remain the sole property of MediciNova. Upon termination or expiration of this Agreement, or upon the request of MediciNova, Consultant agrees to
immediately cease using and return to MediciNova all Proprietary Information (including all whole and partial copies, extracts and derivatives thereof), whether in Consultant’s possession or under Consultant’s direct or indirect control.

 3.3 Exclusions. The foregoing restrictions on use and disclosure shall not apply to any Proprietary Information to the extent
Consultant can prove such Proprietary Information (a) is or has become generally known to the public through no unlawful act of Consultant; (b) was known to Consultant prior to the time of its disclosure by MediciNova, as evidenced by
Consultant’s written records; or (c) becomes known to Consultant from a source other than MediciNova lawfully having possession of and the right to disclose such Proprietary Information, as evidenced by Consultant’s written records.
In addition, notwithstanding Section 3.2 above, Consultant may disclose any Proprietary Information to the extent that Consultant is legally compelled to disclose such Proprietary Information, provided that Consultant shall give advance notice
of such compelled disclosure to MediciNova and shall cooperate with MediciNova in connection with any efforts to prevent or limit the scope of such disclosure and/or use of the Proprietary Information. 
 4. Ownership of Work Product. 
 4.1
Work Product. Consultant agrees that any and all designs, ideas, developments, discoveries, improvements, inventions, technology, works of authorship and other creations conceived, written, created or first reduced to practice in the performance
of Services under this Agreement, together with all intellectual property rights relating thereto (“Work Product”), shall be the sole and exclusive property of MediciNova and shall be deemed part of the Proprietary Information for purposes
of this Agreement. Except to the extent expressly set forth in this Agreement, Work Product shall include, without limitation, all deliverables and other materials prepared, accumulated or developed by Consultant in connection with the Services,
whether or not delivered to MediciNova. Consultant hereby irrevocably assigns to MediciNova all its right, title and interest in and to any and all such Work Product, including, without limitation, all copyrights, trademarks, trade secrets, patents
and all other intellectual property and 

  

 2 

 
proprietary rights related thereto, whether existing now or in the future, effective immediately upon the inception, conception, creation or development
thereof. Consultant further agrees that MediciNova possesses and shall retain all right, title and interest in all Work Product under this Agreement. 
 4.2 Assistance. Consultant agrees (a) to disclose promptly to MediciNova all Work Product and (b) to execute all written instruments (including, without limitation, all patent applications, invention
assignments and copyright assignments) and do such other acts as reasonably required in the opinion of MediciNova to obtain a patent, register a copyright or otherwise evidence, perfect or enforce MediciNova’s right, title and interest in and
to such Work Product. Reasonable costs related to such assistance, if required, shall be paid by MediciNova. Consultant’s obligation to assist MediciNova as described above in this Section 4.2 shall continue beyond the termination of this
Agreement. If MediciNova is unable, after reasonable effort, to secure Consultant’s signature on any document as provided in this Section 4.2, Consultant hereby designates and appoints MediciNova and its duly authorized officers and agents
as its agent and attorney in fact to undertake such acts and to do all other lawfully permitted acts necessary to achieve the intent of this Section 4 with the same legal force and effect as if executed by Consultant. 
 5. Conflicting Engagements. Consultant will notify MediciNova in writing prior to entering into any employment or consulting arrangement with one
or more third parties which involves either subject matter substantially similar to any Services that Consultant is to provide hereunder or services which Consultant is to provide for the benefit of third parties who are competitors of MediciNova.
During the term of this Agreement, Consultant shall not accept work or enter into any agreement or accept any obligation that is inconsistent or incompatible with Consultant’s obligations under this Agreement or which may involve use or
disclosure of any Proprietary Information other than as permitted hereunder. Consultant represents and warrants that, to the best of its knowledge, there is no other existing agreement or duty on Consultant’s part inconsistent with this
Agreement. 
 6. Term; Termination. 
 6.1 The term of this Agreement shall commence on the Effective Date and remain in full force and effect for a period of four (4) months. Either MediciNova or Consultant may terminate this Agreement at any
time, with or without cause, upon thirty (30) days prior written notice to the other, and MediciNova may terminate this Agreement immediately upon a breach of this Agreement by Consultant. 
 6.2 In the event this Agreement is terminated, Consultant shall cease all Services immediately after receiving notice from MediciNova, return all
Proprietary Information (including all copies, extracts and derivatives thereof) as provided in Section 3, deliver to MediciNova all Work Product (including all Work Product then in progress) and related documentation and property belonging to
MediciNova, and provide MediciNova with an invoice for any completed Services for which compensation has not already been paid. Unless this Agreement has been terminated by MediciNova for breach by Consultant, MediciNova agrees to pay Consultant
compensation due for Services actually rendered prior to the date of termination. If compensation has been advanced to Consultant, Consultant shall reimburse any amounts for which any Services have not been performed prior to the date of the notice
of termination. Notwithstanding expiration or termination of this Agreement for any reason, any rights and obligations, which by their nature should survive, will remain in full force and effect. In particular, Sections 3, 4, 6, 9, 10, 11, 12 and 14
shall survive the expiration or termination of this Agreement. 
 7. Compliance With Applicable Laws and Policies. Consultant
warrants that all materials supplied and Services performed under this Agreement shall be in compliance with all applicable laws, rules, ordinances and regulations (“Applicable Law”) as well as any and all of MediciNova’s written
policies and procedures, including handbooks, policy manuals and codes of ethics. 
  

 3 

 8. Independent Contractor. Consultant is acting in the capacity of an independent contractor
hereunder, and nothing contained herein shall be construed or deemed to create an agency, partnership, joint venture or an employee/employer relationship between MediciNova and Consultant. MediciNova shall not make any deductions from any amounts
payable to Consultant for taxes. Consultant shall be solely responsible for all tax returns and payments required to be filed with or made to any federal, state or local tax authority, including, but not limited to, any withholding taxes,
self-employment taxes, and social security, unemployment or disability insurance or similar items, including interest and penalties thereon, with respect to Consultant’s performance of services and receipt of fees under this Agreement.

 9. Legal and Equitable Remedies. Consultant hereby acknowledges that any remedy at law for any violation of the provisions of this
Agreement, including, without limitation, the actual or threatened disclosure of Proprietary Information without the prior express written consent of MediciNova, will be inadequate and that MediciNova may suffer irreparable damage through any such
violation and that therefore, in addition to any other remedies it may have, MediciNova may seek and obtain injunctive relief against a breach or threatened breach of such obligations of Consultant and Consultant shall be liable for all of
MediciNova’s costs and reasonable attorneys’ fees incurred in connection therewith, to the maximum extent permitted by Applicable Law. 
 10. Business Relationships. Consultant acknowledges that MediciNova’s relationships with its employees, partners and third party service providers are valuable business assets. Consultant agrees that, during the term of this
Agreement and for one (1) year thereafter, Consultant shall not (for itself or for any third party) divert or attempt to divert from MediciNova any business, employee, partner or third party service provider, through solicitation or otherwise,
without the prior written consent of MediciNova. 
 11. Warranties. Consultant represents and warrants that (a) Consultant is
duly formed and validly existing under the laws of the State of Delaware and has the full power and authority to enter into this Agreement and to perform its obligations hereunder; (b) Consultant has good and marketable title to all of
Consultant’s Work Product and has the right to grant the rights and assignments granted herein, without the need for any assignments, releases, consents or approvals not yet obtained; (c) the Work Product shall not be subject to any
restrictions or to any claims, mortgages, liens, pledges, security interests, encumbrances, encroachments or demands of third parties, including any claims by any such third parties with respect to such third parties’ intellectual property
rights in the Work Product; (d) the Work Product does not and shall not infringe, misappropriate or violate any patent, copyright, trademark, trade secret or other proprietary rights of any third party; and (e) the Services, including any
deliverables required hereunder, shall be performed in accordance with professional standards and shall substantially conform to any specifications for such Services and/or deliverables as set forth or referenced in the Statement of Work. In
addition, in the event that MediciNova provides Consultant with prior written approval to engage any third parties in the performance of any Services, Consultant represents and warrants that (i) Consultant shall be responsible for managing any
permitted subcontractors hereunder and (ii) all permitted subcontracts shall contain all of the material terms and conditions set forth in this Agreement. 
 12. Use of MediciNova Name. Consultant shall not make any written use or reference to MediciNova’s name for any marketing, public relations, advertising, display or other business purpose without the prior
written consent of MediciNova, which consent may be granted or withheld in MediciNova’s sole and absolute discretion. 
  

 4 

 13. Notices. (a) Any notices required or permitted hereunder shall be given to the appropriate
party at the address specified at below (or at such other address as the party shall specify in writing). Such notice shall be deemed given either (a) upon personal delivery, (b) one (1) business day after being sent by overnight
delivery service, or (c) on the day of transmission by facsimile, provided that the notifying party confirms receipt of such transmission with the other party by telephone. 
  

			
	If to MediciNova:	    	MediciNova, Inc.
		    	4350 La Jolla Village Drive, Suite 950
		    	San Diego, CA 92122
		    	Attention: Shintaro Asako
		    	Telephone: 858-373-1500
		    	Fax: 858-373-7000
		    	Email: asako@medicinova.com
		
	If to Consultant:	    	Danerius, LLC

 14. General. The parties’ rights and obligations under this Agreement will bind and
inure to the benefit of their respective successors and assigns, except that Consultant may not delegate or assign any of his or her obligations or rights under this Agreement without MediciNova’s prior written consent. This Agreement, and the
Exhibit attached hereto and hereby incorporated herein, constitute the parties’ final, exclusive and complete understanding and agreement with respect to the subject matter hereof and supersede all prior and contemporaneous understandings and
agreements relating to its subject matter. This Agreement may not be modified or amended unless mutually agreed upon in writing by both parties. The waiver by either party of a breach of or a default under any provision of this Agreement shall not
be effective unless in writing and shall not be construed as a waiver of any subsequent breach of or default under the same or any other provision of this Agreement, nor shall any delay or omission on the part of either party to exercise or avail
itself of any right or remedy that it has or may have hereunder operate as a waiver of any such right or remedy. If any provision of this Agreement shall be held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable,
such provision shall be enforced to the maximum extent possible so as to effect the intent of the parties, or, if incapable of such enforcement, shall be deemed to be deleted from this Agreement, and the remainder of this Agreement shall remain in
full force and effect. The laws of the State of California, excluding its conflicts of laws principles, shall govern this Agreement. TO THE FULLEST EXTENT PERMITTED BY LAW, THE PARTIES HEREBY IRREVOCABLY WAIVE THE RIGHT TO A TRIAL BY JURY IN ANY
ACTION RELATED TO THIS AGREEMENT. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute a single instrument. 
 [Signature Page Follows] 
  

 5 

 IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first set forth above. 
  

									
	MEDICINOVA	 		 	CONSULTANT
					
	By:	 	 /s/    Shintaro Asako
	 		 	By:	 	 /s/    Alan W. Dunton

			
	 Shintaro Asako
	 		 	 Alan W. Dunton

	Name	 		 	Name
			
	 Vice President and Chief Financial Officer
	 		 	 President

	Title	 		 	Title

  

 6 

 EXHIBIT A 
 STATEMENT OF WORK 
 Services: Subject at all times to consultation with the Chief Executive Officer, Chief
Financial Officer and MediciNova’s Board of Directors or their designated representatives, Consultant shall assist and advise MediciNova in connection with MediciNova’s product development programs and development activities. Consultant
shall provide all such Services as the Chief Executive Officer may reasonably request from time to time. 
 Type or Rate of Payment: Consultant shall
be paid at the rate of Twenty-Seven Thousand Five Hundred Dollars ($27,500.00) per month, commencing as of the Effective Date of this Agreement, for the term of the Agreement. 
 Timing of Payment(s): Consultant shall invoice MediciNova upon execution of this Agreement in the amount of Twenty-Seven Thousand Five Hundred
Dollars ($27,500.00) for the first month of the Services and thereafter on the fifteenth (15th) day of each month for subsequent monthly payments due hereunder. Each invoice shall include complete support documentation for all expenses incurred in performance of the Services. All undisputed amounts set forth in each invoice
shall be due and payable within thirty (30) business days from receipt by MediciNova of Consultant’s invoice therefor. 
 Expenses:
Consultant shall be reimbursed for reasonable, documented expenses incurred while performing the Services that are preapproved by MediciNova in accordance with Section 2.2 of this Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]